Cargando…
Palovarotene for Fibrodysplasia Ossificans Progressiva (FOP): Results of a Randomized, Placebo‐Controlled, Double‐Blind Phase 2 Trial
Fibrodysplasia ossificans progressiva (FOP) is an ultra‐rare genetic disorder characterized by progressive heterotopic ossification (HO), often heralded by flare‐ups, leading to reduced movement and life expectancy. This placebo‐controlled, double‐blind trial (NCT02190747) evaluated palovarotene, an...
Autores principales: | Pignolo, Robert J., Baujat, Geneviève, Hsiao, Edward C., Keen, Richard, Wilson, Amy, Packman, Jeff, Strahs, Andrew L., Grogan, Donna R., Kaplan, Frederick S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9804935/ https://www.ncbi.nlm.nih.gov/pubmed/35854638 http://dx.doi.org/10.1002/jbmr.4655 |
Ejemplares similares
-
Study methodology and insights from the palovarotene clinical development program in fibrodysplasia ossificans progressiva
por: Pignolo, Robert J., et al.
Publicado: (2023) -
OR29-05 A Natural History Study of Fibrodysplasia Ossificans Progressiva (FOP): 12-Month Outcomes
por: Mukaddam, Mona Al, et al.
Publicado: (2020) -
Fibrodysplasia Ossificans Progressiva (FOP): A Segmental Progeroid Syndrome
por: Pignolo, Robert J., et al.
Publicado: (2020) -
Special considerations for clinical trials in fibrodysplasia ossificans progressiva (FOP)
por: Hsiao, Edward C., et al.
Publicado: (2018) -
Prevalence of fibrodysplasia ossificans progressiva (FOP) in the United States: estimate from three treatment centers and a patient organization
por: Pignolo, Robert J., et al.
Publicado: (2021)